Jazz Pharmaceuticals plc research snapshot
JAZZ AI stock analysis currently reads Jazz Pharmaceuticals plc as a global rare-disease biopharma with a diversified neuroscience and oncology portfolio, strong cash flow, and a valuation that looks low on forward non-GAAP earnings but leaves little room for pipeline disappointment. At the July 12, 2026 cutoff, the latest verified close was $243.82 on July 10, 2026, market capitalization was about $15.32 billion, and the main question was whether Xywav can keep growing, zanidatamab can win and launch in first-line HER2-positive gastroesophageal adenocarcinoma, and the oncology launches can offset generic Xyrem pressure. This is informational research and not investment advice.
Current price
$243.82
Market cap
$15.32 billion
AI score
72 / 100
Rating
Quality rare-disease platform with a thin margin of safety
Trend status
Strong long-term uptrend near 52-week highs
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Jazz is a global biopharma focused on rare diseases, with a diversified portfolio across neuroscience and oncology, more than $4 billion in annual revenue, and strong free cash flow. | High |
| Moat | The moat comes from orphan-drug exclusivity, patent protection, specialist commercial teams, and patient access programs. Xywav has defended against generic Xyrem, and oncology launches are gaining traction. | Medium-high |
| Management | Renee Gala became CEO in August 2025 after serving as CFO, President, and COO. The leadership team has delivered 21 consecutive years of revenue growth, disciplined M&A, and debt paydown. | Medium-high |
| Financial trend | Q1 2026 total revenues grew 19% year over year to $1.07 billion, and 2026 guidance is $4.25 billion to $4.50 billion. TTM free cash flow is about $1.27 billion, while TTM GAAP net income is only $29.45 million due to amortization and one-time items. | High |
| Valuation | At the cutoff, JAZZ traded near 10x forward non-GAAP earnings and 12x TTM free cash flow. The TTM GAAP PE is distorted and not useful. The valuation is reasonable for success, but the margin of safety is thin. | Medium |
| Technical trend | JAZZ is above its 50-day and 200-day moving averages, RSI is 64.79, and the stock is near 52-week highs. The trend is strong but extended. | Medium-high |
| Risk level | Key risks are Xyrem generic erosion, zanidatamab PDUFA and commercial uptake, pipeline trial outcomes, pricing and payor pressure, and debt. | High |
| AI confidence | High data confidence for reported financials, market data, and product facts. Lower confidence for pipeline success and future price targets. | High data confidence |
| Investment certainty | Medium. The business is strong and the valuation is low, but the stock has already run up and the pipeline is not fully de-risked. | Medium |
JAZZ AI stock forecast
The JAZZ AI stock forecast uses scenario ranges around the $243.82 July 10, 2026 close. It does not claim that AI can predict a specific price. The bullish case depends on zanidatamab approval, continued Xywav growth, oncology launches beating expectations, and the market maintaining a premium multiple. The base case assumes 2026 guidance is met and the forward multiple stays near 10x. The bearish case assumes pipeline disappointment or generic erosion.
$315 to $345
More likely if zanidatamab is approved on or before its August 2026 PDUFA date, Xywav grows faster than guidance, Modeyso and Zepzelca exceed launch expectations, and the market assigns a 12x to 14x forward earnings multiple.
$245 to $270
More likely if Jazz delivers 2026 revenue of $4.25 billion to $4.50 billion, Xywav is flat to up mid-single digits, and the stock continues to trade near 10x forward non-GAAP earnings.
$155 to $180
More likely if zanidatamab is delayed or rejected, Xywav prescriptions stall, generic oxybate pressure accelerates, or the market resets the multiple toward 7x to 8x forward earnings.
JAZZ AI technical analysis
JAZZ AI technical analysis starts from the $243.82 July 10, 2026 close. Public technical sources showed the stock above the 50-day and 200-day moving averages, with RSI near 65 and below-average volume. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $243.82 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $230 to $232 | Support planning zone around the 50-day moving average reported by public technical sources. |
| Secondary support | $220 to $225 | A recent congestion and breakout area. A sustained break would weaken the near-term setup. |
| Near resistance | $248 to $250 | The 52-week high zone and recent trading range highs. Breakout attempts need volume confirmation. |
| 50-day moving average | $230.22 | StockAnalysis showed JAZZ above the 50-day moving average around the cutoff. |
| 200-day moving average | $182.14 | Public technical sources showed JAZZ well above its 200-day moving average, supporting the long trend. |
| Momentum | RSI 64.79, MACD positive | RSI is near the upper end of neutral but not yet overbought. MACD remained positive on available snapshots. |
| Volume | 626,454 shares | The July 10 volume was below the 20-day average of about 878,413 shares, so a breakout should be confirmed by participation. |
| Volatility | ATR 14 near $6.19 | Position sizing should allow for normal daily movement around the cutoff price. |
| Invalidation | Close below $230, then $220 | A close below the 50-day area would weaken the near-term setup. A break below the recent breakout area would challenge the trend. |
JAZZ AI trading strategy
The JAZZ AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for JAZZ to hold above the 50-day area and break the $248 to $250 resistance zone with above-average volume before treating momentum as confirmed.
A failed breakout or daily close below the 50-day area should reduce confidence in the setup.
If JAZZ pulls back toward $230 to $232 without a thesis break, compare price stabilization with the August 2026 zanidatamab PDUFA date and the August 4, 2026 earnings report.
Do not average down solely because the valuation looks low. Define maximum loss and review the regulatory and pipeline calendar first.
Track 2026 revenue guidance, Xywav prescription trends, Epidiolex growth, zanidatamab PDUFA and launch execution, Modeyso uptake, and debt reduction.
Lower the rating if pipeline data disappoints or if the stock rises faster than the underlying earnings power.
Investment research summary
Jazz develops and commercializes medicines for rare and serious diseases, with a focus on neuroscience and oncology. Its largest products are Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for severe epilepsies, and a growing oncology portfolio. Customers are patients, physicians, and payors, and revenue comes from product sales, royalties, and milestone payments.
The moat is a combination of orphan-drug exclusivity, patent protection, specialist commercial teams, and patient access programs. Xywav has defended its low-sodium position against generic Xyrem, and oncology launches are gaining physician adoption. The moat is stronger when the company has scarce therapies and weaker when it relies on older products facing generic competition.
The thesis can fail if zanidatamab is delayed or rejected, Xywav growth stalls, generic oxybate erodes pricing, a key pipeline trial fails, or the market pays a lower multiple for mid-single digit growth. The stock has already rallied 126% over 52 weeks, so expectations are higher than they were a year ago.
Renee Gala became CEO in August 2025 after serving as CFO, President, and COO. She has a background in finance, strategy, and corporate development. The leadership team has a record of revenue growth, disciplined M&A, debt paydown, and successful launches such as Epidiolex and Modeyso.
Rare-disease and specialty biopharma is a long-term trend driven by unmet medical need, orphan-drug incentives, personalized medicine, and aging populations. Jazz is positioned in neuroscience and oncology, but it also faces pricing scrutiny, regulatory risk, and competition from generics and large-cap biopharma.
At $243.82, JAZZ trades at roughly 10x forward non-GAAP earnings and 12x TTM free cash flow. The TTM GAAP PE is distorted and not useful. The three-scenario model points to a base case around $257 if the company meets 2026 guidance and keeps a 10x multiple. The margin of safety is narrow because the stock has moved up sharply and the pipeline is not fully de-risked.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| JAZZ price | $243.82 close on July 10, 2026 | Yahoo Finance historical quote snapshot | July 12, 2026 |
| Market capitalization | $15.32 billion, verified as $243.82 x 62.82M shares | financial_rigor.py market cap verification and StockAnalysis shares outstanding | July 12, 2026 |
| Shares outstanding | 62.82 million | StockAnalysis and AlphaQuery quarterly shares outstanding | July 12, 2026 |
| Q1 2026 total revenues | $1,068.9 million | Jazz Pharmaceuticals Q1 2026 earnings release and SEC 10-Q | July 12, 2026 |
| Q1 2026 GAAP diluted EPS | $4.43 | Jazz Pharmaceuticals Q1 2026 SEC 10-Q | July 12, 2026 |
| Q1 2026 non-GAAP adjusted EPS | $6.34 | Jazz Pharmaceuticals Q1 2026 earnings release | July 12, 2026 |
| FY2025 total revenues | $4,267.6 million | Jazz Pharmaceuticals 2025 annual report on Form 10-K | July 12, 2026 |
| FY2025 non-GAAP adjusted EPS | $8.38 | Jazz Pharmaceuticals 2025 annual report on Form 10-K | July 12, 2026 |
| TTM revenue | $4.44 billion | StockAnalysis and SEC-derived cross-check | July 12, 2026 |
| TTM free cash flow | $1.27 billion | StockAnalysis statistics | July 12, 2026 |
| Cash and investments | $2.9 billion at March 31, 2026 | Jazz Pharmaceuticals Q1 2026 SEC 10-Q | July 12, 2026 |
| Total debt | $5.42 billion | StockAnalysis statistics | July 12, 2026 |
| Forward PE | 10.06x | StockAnalysis statistics | July 12, 2026 |
| Consensus price target | $257.95 | StockAnalysis analyst estimates | July 12, 2026 |
| Moving averages and momentum | 50-day MA $230.22, 200-day MA $182.14, RSI 64.79 | StockAnalysis statistics | July 12, 2026 |
| Three-scenario valuation | Bull $335.9, base $257.2, bear $166.3 from financial_rigor.py | financial_rigor.py three-scenario model | July 12, 2026 |
This JAZZ AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
